Results 41 to 50 of about 922,637 (337)

Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis

Frontiers in Medicine, 2021
Biological therapies, such as TNF inhibitors (TNFi), are increasing remission (REM) rates in rheumatoid arthritis (RA) patients, although these are still limited.
Borja Hernández-Breijo, Chamaida Plasencia-Rodríguez, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, Victoria Navarro-Compán, Carlota García-Hoz, Israel Nieto-Gañán, Cristina Sobrino, Javier Bachiller-Corral, Mariana Díaz-Almirón, Ana Martínez-Feito, Ana Martínez-Feito, Teresa Jurado, Paloma Lapuente-Suanzes, Gema Bonilla, Cristina Pijoán-Moratalla, Garbiñe Roy, Mónica Vázquez-Díaz, Alejandro Balsa, Alejandro Balsa, Luisa M. Villar, Dora Pascual-Salcedo, Eulalia Rodríguez-Martín   +22 more
doaj   +1 more source

Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn’s disease patients who failed infliximab therapy: The Italian society of pediatric gastroenterology, hepatology, and nutrition experience [PDF]

, 2019
Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.
Accomando S., Aloi M., Alvisi P., Arrigo S., Balzani L., Cucchiara S., De Giacomo C., Gennari M., Guariso G., Knafelz D., Lionetti P., Martelossi S., Miele E., Ravelli A., Romano C., Zuin G.   +15 more
core   +1 more source

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.

Gastroenterology, 2020
BACKGROUND & AIMS We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS We collected follow-up data from 122 patients (mean age, 31.2±11.3 y) with early, moderate to severe CD (median duration 0.2 y;
R. Ungaro, C. Yzet, P. Bossuyt, F. Baert, T. Vaňásek, G. D'Haens, V. Joustra, R. Panaccione, G. Novacek, W. Reinisch, A. Armuzzi, O. Golovchenko, O. Prymak, A. Goldiş, S. Travis, X. Hébuterne, M. Ferrante, G. Rogler, M. Fumery, S. Danese, G. Rydzewska, B. Pariente, E. Hertervig, C. Stanciu, M. Serrero, M. Diculescu, L. Peyrin-Biroulet, D. Laharie, J. P. Wright, F. Gomollón, I. Gubonina, S. Schreiber, S. Motoya, P. Hellström, J. Halfvarson, J. Butler, J. Petersson, F. Petralia, J. Colombel   +38 more
semanticscholar   +1 more source

Difficult to treat absence seizures in children: A single-center retrospective study

Frontiers in Neurology, 2022
ObjectivesThe aim of this study was to analyse the characteristics of typical absence seizures (AS), myoclonic AS and AS with eyelid myoclonia in children and to find associations between these characteristics and difficult to treat absence seizures ...
Samo Gregorčič, Jaka Hrovat, Neli Bizjak, Neli Bizjak, Zvonka Rener Primec, Zvonka Rener Primec, Tadeja Hostnik, Blaž Stres, Blaž Stres, Blaž Stres, Mirjana Perković Benedik, Mirjana Perković Benedik, Damjan Osredkar, Damjan Osredkar   +13 more
doaj   +1 more source

Probiotics for maintenance of remission in ulcerative colitis.

Cochrane Database of Systematic Reviews, 2020
BACKGROUND Ulcerative colitis is an inflammatory condition affecting the colon, with an annual incidence of approximately 10 to 20 per 100,000 people. The majority of people with ulcerative colitis can be put into remission, leaving a group who do not ...
Zipporah Iheozor-Ejiofor, Lakhbir Kaur, M. Gordon, Patricia Anne Baines, V. Sinopoulou, A. Akobeng   +5 more
semanticscholar   +1 more source

Can remission be in juvenile idiopathic arthritis without the use of biological agents?

Современная ревматология, 2019
Objective: to evaluate the efficiency and safety of therapy with subcutaneous (SC) methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.Patients and methods.
S. I. Valieva, A. A. Glazyrina, N. N. Kuleshov, M. S. Dzis, S. Kh. Kurbanova, A. S. Sologub, E. A. Korobiyants, V. T. Yusupova   +7 more
doaj   +1 more source

Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]

, 2009
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core   +2 more sources

Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Gastroenterology, 2020
BACKGROUND & AIMS Clinical remission, defined by a composite of patient reported outcomes and Mayo endoscopy subscore (MES) 0 or 1 is a recommended treatment target in patients with ulcerative colitis (UC).
H. Yoon, S. Jangi, P. Dulai, B. Boland, L. Prokop, V. Jairath, B. Feagan, W. Sandborn, Siddharth Singh   +8 more
semanticscholar   +1 more source

Evaluation of the efficiency and safety of tocilizumab therapy in patients with systemic-onset juvenile idiopathic arthritis: results of a retrospective follow-up

Современная ревматология, 2018
Objective: to study the efficiency and safety of tocilizumab (TCZ) therapy in patients with systemic-onset juvenile idiopathic arthritis (sJIA). Patients and methods.
M. M. Kostik, E. A. Isupova, I. A. Chikova, M. F. Dubko, V. V. Masalova, L. S. Snegireva, O. V. Kalashnikova, V. G. Chasnyk   +7 more
doaj   +1 more source

Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy

Clinical Case Reports, 2021
DS‐ALL has a higher rate of relapse and treatment‐related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis.
Zhongbo Hu, Kristen A. VanHeyst, Jignesh Dalal, Lisa Hackney   +3 more
doaj   +1 more source